@manas_co , an AI-driven drug discovery startup, has secured $24.6 million in seed funding led by @reidhoffman , @generalcatalyst , and Greylock Partners. The company is set to revolutionize cancer treatment by leveraging AI to analyze molecules 100 times faster than traditional methods, drastically reducing drug development timelines from a decade to just a few years. With @Azure ’s cloud computing and support from @Microsoft 's AI expertise, Manas AI is collaborating with top scientists, including Nobel laureates and National Academy members, to accelerate breakthroughs in breast cancer, prostate cancer, and lymphoma treatments. Though its funding is modest compared to @Xaira_Thera ($1B) and Treeline Biosciences ($422M), Manas AI aims to make a major impact in precision-designed AI-driven medicine. The announcement was made during Reid Hoffman’s presentation for his latest book, Superagency: What Could Possibly Go Right with Our AI Future.